- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
- Latest weekly return ranks in the strongest part of its sector group.
ALBPS
PAR
Week ended 07 Aug 2026
Weekly Investor Report
Biophytis S.A. · Healthcare · Biotechnology
Latest close
0.03 EUR
381.8%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 10.2% above the Trend Line and sits at 13.6% of its 52-week range. The latest completed week returned 381.8%, after a 107.8% four-week move. The latest news-sentiment score is 48/100.
Setup score
41
out of 100
Latest Close
0.03 EUR
7 Aug 2026
1W Return
381.8%
latest completed week
4W Return
107.8%
short-term follow-through
12W Return
52.9%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
9.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 26.14% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
381.8%
Latest completed week; four-week move 107.8%.
Indicator stack
0/73
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 26.14%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
48/100
4 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 10.2% above the Trend Line and sits at 13.6% of its 52-week range. The latest completed week returned 381.8%, after a 107.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 9.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0112-week average 0.02
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 107.8% over four weeks, 52.9% over 12 weeks, and -82.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.17Latest activity-pressure read.
Pressure change25.6%Four-week change in activity pressure.
Leadership-56.35Latest relative-leadership reading.
RS change30.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment48/100
Weighted news tone is neutral across 4 relevant articles.
0 positive · 3 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-84.7%Distance below the 52-week high.
13-week volatility104.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher5 of 2615 weeks finished lower.
Best week+381.8%Week of 7 Aug.
Worst week-56.9%Week of 31 Jul.
Latest week+381.8%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains2
Flat weeks6
Modest losses4
Sharp losses11
Recent vol104.8%13-week weekly-return volatility.
Base vol54.4%52-week weekly-return volatility.
Up/down split12/34Count of positive and negative weeks in the 52-week window.
Average skew36.6% / -9.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorFR Healthcare
4-week rank1 / 76
Group average0.7%
Trend breadth26.3%
Trend26.3%active weekly trend signals
MD40.8%positive activity pressure
RS19.7%positive relative leadership
Four-week leaders
IndustryFR Biotechnology
4-week rank1 / 33
Group average4.5%
Trend breadth27.3%
Trend27.3%active weekly trend signals
MD36.4%positive activity pressure
RS21.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape30/100
Trend, activity pressure, participation, and risk combine to a 30/100 tape read.
Indicator analysis29/100Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.
Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 26.14%Next-week expectancy is negative with a 26.14% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment48/100Weighted news tone is neutral across 4 relevant articles.
BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.03 EUR | 381.8% | 0.03 EUR | 0.82 EUR | 1.17 | -56.35 | 355.0M | Off |
| 31 Jul 2026 | 0.01 EUR | -56.9% | 0.03 EUR | 0.86 EUR | 0.83 | -91.12 | 41.7M | Off |
| 24 Jul 2026 | 0.02 EUR | 0.0% | 0.03 EUR | 0.89 EUR | 0.98 | -80.17 | 0 | Off |
| 17 Jul 2026 | 0.02 EUR | 0.0% | 0.03 EUR | 0.94 EUR | 0.95 | -80.83 | 0 | Off |
| 10 Jul 2026 | 0.02 EUR | 0.0% | 0.04 EUR | 0.99 EUR | 0.93 | -81.49 | 0 | Off |
| 3 Jul 2026 | 0.02 EUR | 0.0% | 0.04 EUR | 1.04 EUR | 0.89 | -82.37 | 0 | Off |
| 26 Jun 2026 | 0.02 EUR | 0.0% | 0.04 EUR | 1.09 EUR | 0.84 | -82.61 | 0 | Off |
| 19 Jun 2026 | 0.02 EUR | 0.0% | 0.04 EUR | 1.14 EUR | 0.76 | -83.15 | 0 | Off |
| 12 Jun 2026 | 0.02 EUR | -19.0% | 0.04 EUR | 1.20 EUR | 0.61 | -83.46 | 1.9M | Off |
| 5 Jun 2026 | 0.02 EUR | -5.5% | 0.05 EUR | 1.25 EUR | 0.59 | -79.78 | 580.0K | Off |
| 29 May 2026 | 0.02 EUR | 5.8% | 0.05 EUR | 1.31 EUR | 0.47 | -79.04 | 8.9M | Off |
| 22 May 2026 | 0.02 EUR | -9.1% | 0.05 EUR | 1.36 EUR | 0.41 | -80.50 | 13.8M | Off |
| 15 May 2026 | 0.02 EUR | -1.0% | 0.06 EUR | 1.42 EUR | 0.35 | -78.68 | 44.4M | Off |
| 8 May 2026 | 0.02 EUR | 0.5% | 0.06 EUR | 1.48 EUR | -0.06 | -79.42 | 28.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.